TITLE

Identification of risk factors and characteristics of supraclavicular lymph node metastasis in patients with small cell lung cancer

AUTHOR(S)
Feng, Zhen-Xing; Zhao, Lu-Jun; Guan, Yong; Sun, Yao; Meng, Mao-Bin; Ji, Kai; Wang, Ping
PUB. DATE
March 2013
SOURCE
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Thoracic radiotherapy provides a survival benefit in patients with limited-stage disease of small cell lung cancer (LS-SCLC), but inclusion and exclusion of prophylactic irradiation of the supraclavicular area are still controversial. This study analyses the risk factors and characteristics of lymph node metastases in the supraclavicular area of LS-SCLC patients, which could help in developing a better radiotherapy for the patients. A total of 239 patients with LS-SCLC were included in this retrospective analysis. Clinical characteristics and mediastinal lymph node metastasis were analyzed for association with SCM, and the SCM pattern was further analyzed based on the treatment planning CT scans. The SCM incidence was 34.7 % (83 of 239). The multivariate analysis showed that only the mediastinal level 2 (OR = 16.101, P = 0.000) and level 3 (OR = 5.597, P = 0.000) lymph node metastases were significantly associated with SCM. As the most frequently involved region, supraclavicular level I lymph node metastases were identified in 61 of 83 patients (73.5 %), followed by level III, level IV, level V, and level II lymph node metastases, accounting a total of 95.2 % for level I and/or III lymph node metastases, whereas the incidence of skip metastasis was only 4.8 %. SCLC patients with mediastinal level 2 and level 3 lymph node metastasis were at high risk of SCM. If prophylactic irradiation therapy is considered, the nodal clinical target volume of irradiation should include bilateral lower para-recurrent laryngeal neural region (level I) and the para-internal jugular venous region (level III).
ACCESSION #
85859823

 

Related Articles

  • Morphometric analysis of regional lymph nodes in surgically resected non-small cell lung cancer. Gotoh, Hajimu; Kanomata, Naoki; Yoshimura, Masahiro; Ohno, Yoshiharu; Moriya, Takuya; Ohbayashi, Chiho // Medical Molecular Morphology;Sep2009, Vol. 42 Issue 3, p162 

    Nodal staging is a crucial factor in choosing the treatment option for non-small cell lung cancer (NSCLC). However, so far as we know, a computer-based histomorphometric analysis of lymph nodes in NSCLC has never been developed. We studied 299 surgically resected lymph nodes from 108 patients...

  • Lymphatic Vessel Density Is Not Associated With Lymph Node Metastasis in Non--Small Cell Lung Carcinoma. Faoro, Leonardo; Hutto, Joann Y.; Salgia, Ravi; El-Zayaty, Shady A.; Ferguson, Mark K.; Cheney, Richard T.; Reid, Mary E.; Armato III, Samuel G.; Krausz, Thomas; Husain, Aliya N. // Archives of Pathology & Laboratory Medicine;Dec2008, Vol. 132 Issue 12, p1882 

    Context.--Angiogenesis is essential for tumors to grow and metastasize. Lymphatic metastasis is also an important means of tumor spread. In non-small cell lung carcinoma, the relationship of lymphangiogenesis with lymph node metastasis and, ultimately, patient prognosis is unknown....

  • Role of positron emission tomography in mediastinal lymphatic staging of non-small cell lung cancer. Melek, Huseyin; Gunluoglu, Mehmet Zeki; Demir, Adalet; Akin, Hasan; Olcmen, Aysun; Dincer, Seyyit Ibrahim // European Journal of Cardio-Thoracic Surgery;Feb2008, Vol. 33 Issue 2, p294 

    Abstract: Objective: Positron emission tomography (PET) is used increasingly in staging of non-small cell lung cancer (NSCLC) as a non-invasive tool. The role of the PET in mediastinal lymphatic staging of NSCLC is not clear. We aimed to demonstrate the efficacy of PET in determining mediastinal...

  • Risk factors for brain metastases in surgically staged IIIA non-small cell lung cancer patients treated with surgery, radiotherapy and chemotherapy. Petrović, Marina; Ilić, Nevenka; Lončarević, Olivera; Čekerevac, Ivan; Lazić, Zorica; Novković, Ljiljana; Ćupurdija, Vojislav; Kostić, Gordana // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Aug2011, Vol. 68 Issue 8, p643 

    Introduction/Aim. Lung cancer is a leading cause of mortality among patients with carcinomas. The aim of this study was to point out risk factors for brain metastases (BM) appearance in patients with IIIA (N2) stage of non- small cell lung cancer (NSCLC) treated with three-modal therapy....

  • Overexpression of Osteopontin, αvβ3 and Pim-1 Associated with Prognostically Important Clinicopathologic Variables in Non-Small Cell Lung Cancer. Yi Jin; Da-yue Tong; Jian-ning Chen; Zhi-ying Feng; Jian-yong Yang; Chun-kui Shao; Jia-ping Li // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    In this study, we examined the expression of osteopontin (OPN), αvβ3 and Pim-1 in non-small cell lung cancer (NSCLC) and investigated the potential clinical implications of their expression patterns in NSCLC. Immunohistochemical assays were used to examine the protein expression of OPN,...

  • Contemporaneous Bilateral Forearm Triceps Metastases from Adenocarcinoma of the Lung. Rossi, Antonio; Rosati, Gerardo; Chiacchio, Rosistella; Manzione, Luigi // Oncology;2000, Vol. 59 Issue 1, p28 

    Haematogenous skeletal muscle metastases from non-small-cell lung cancer (NSCLC) are rare, and are even more uncommonly observed bilaterally. Usually, NSCLC metastasizes to the liver, adrenal glands, lung, bone, central nervous system and kidney. We report a case of a long-surviving patient with...

  • MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells. Li, Jipeng; Song, Yulan; Wang, Yiping; Luo, Jianping; Yu, Wanjun // Molecular & Cellular Biochemistry;Aug2013, Vol. 380 Issue 1/2, p277 

    Recent studies have implied that miRNAs act as crucial modulators for epithelial-to-mesenchymal transition (EMT). We found that miR-148a is significantly downregulated in non-small cell lung cancer (NSCLC) compared to adjacent non-cancerous lung tissues, and the downregulated miR-148a was...

  • Dosimetric feasibility of dose escalation using SBRT boost for stage III non-small cell lung cancer. Hepel, Jaroslaw T.; Peter, Justin; Hiatt, Jessica R.; Patel, Salil; Osibanjo, Oluwademilade; Safran, Howard; Curran, Bruce; DiPetrillo, Thomas // Frontiers in Oncology;Sep2012, Vol. 2, p1 

    Purpose: Standard chemoradiation therapy for stage III non-small cell lung cancer (NSCLCa) results in suboptimal outcomes with a high rate of local failure and poor overall survival. We hypothesize that dose escalation using stereotactic body radiotherapy (SBRT) boost could improve upon these...

  • Prognostic Impact of MiR-155 in Non-Small Cell Lung Cancer Evaluated by in Situ Hybridization. Donnem, Tom; Eklo, Katrine; Berg, Thomas; Sorbye, Sveinung W.; Lonvik, Kenneth; Al-Saad, Samer; Al-Shibli, Khalid; Andersen, Sigve; Stenvold, Helge; Bremnes, Roy M.; Busund, Lill-Tove // Journal of Translational Medicine;2011, Vol. 9 Issue 1, p1 

    Background: In recent years, microRNAs (miRNAs) have been found to play an essential role in tumor development. In lung tumorigenesis, targets and pathways of miRNAs are being revealed, and further translational research in this field is warranted. MiR-155 is one of the miRNAs most consistently...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics